Journal: Signal Transduction and Targeted Therapy

Article Title: Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment

doi: 10.1038/s41392-022-01283-6

Figure Lengend Snippet: TP lipo inhibits Delta variant in vitro propagation in Vero E6 cells. Vero E6 cells (5 × 10 4 ) were preincubated with TP lipo for 1 h at 37 °C and then exposed to the Delta variant (MOI = 0.05). a Representative CPE pictures estimated at 72 h postinfection are shown under a microscope. b The percentage of CPE at 24, 48, and 72 h was analyzed from three independent experiments. c qRT-PCR quantification of Delta variant gRNA and sgRNA in infected Vero E6 cells at 24 h postinfection. d qRT-PCR quantification of Delta variant gRNA and sgRNA in supernatants at 72 h postinfection. e Delta variant-infected Vero E6 cells were exposed to Vehicle lipo or a different dose of TP lipo for up to 24 h (MOI = 0.05). Total protein was extracted and subjected to analysis of three phosphorylated protein levels, including p-NF κB p65, p-p38 MAPK, and p-STAT3. Vinculin was used as a loading control. Data represent the mean ± SEM; n = 3. Significance is indicated by: ns no significance; * P ≤ 0.05; *** P ≤ 0.001; **** P ≤ 0.0001

Article Snippet: Next, the membranes were probed overnight at 4 °C with the following primary antibodies: mouse polyclonal anti-p-p38 MAPK (T180/Y182) (Cell Signaling Technology, 1:2000), rabbit polyclonal anti-GAPDH (Santa Cruz Biotechnology, 1:4000), rabbit polyclonal anti-STAT3 (HUABIO, 1:1000), rabbit polyclonal anti-p-STAT3 (Tyr705) (HUABIO, 1:500), rabbit polyclonal anti-p-NF-κB p65 (S536) (Cell Signaling Technology, 1:1000), rabbit polyclonal anti-p38 MAPK (Cell Signaling Technology, 1:2500), rabbit polyclonal anti-NF-κB p65 (Cell Signaling Technology, 1:1000), and mouse polyclonal anti-Vinculin (Sigma, 1:4000).

Techniques: Variant Assay, In Vitro, Microscopy, Quantitative RT-PCR, Infection